Parkinson’s disease researchers: L-R Associate Professor Antony Cooper, Dr Dr Yuxi Zhang, Dr Daniel Hesselson and PhD student Brigitte Phillips.
The Garvan Institute recently became one of the first in the world to acquire technology that can sequence a whole human genome at high throughput and low cost. This gives the Parkinson’s disease research teams an unparalleled ability to undertake whole genome sequencing of patient DNA and animal models of PD, vastly increasing our understanding and leading to better, safer, more effective personalised medicine. Garvan’s Parkinson Disease research program is multidisciplinary, focusing on translating basic scientific discoveries into the clinic where people can be helped.
In a partnership with Cure-Parkinson’s Trust’s (UK) Linked Clinical Trials program, Garvan is committed to holding clinical trials to provide Australians with the opportunity to trial potential neuroprotective drugs that may slow or stop disease progression and the associated worsening of symptoms and the development of new symptoms.